XOPENEX CONCENTRATE Rx
Generic Name and Formulations:
Levalbuterol (as HCl) (single-isomer albuterol) 1.25mg/0.5mL; per vial; soln for inhalation via nebulization after dilution; preservative-free.
Indications for XOPENEX CONCENTRATE:
Initially 0.63mg by nebulization 3 times daily at 6–8 hr intervals; may increase to 1.25mg 3 times daily.
<6yrs: not established. 6–11yrs: 0.31mg by nebulization 3 times daily; max 0.63mg 3 times daily.
Do not exceed recommended dose. Monitor for increased need; if inadequate control, reevaluate and consider adding an antiinflammatory (eg, corticosteroids). Sensitivity to sympathomimetics. Discontinue if paradoxical bronchospasm or cardiovascular effects occur. Cardiovascular disorders (esp. coronary insufficiency, arrhythmias, hypertension). Seizure disorders. Diabetes. Hyperthyroidism. Renal impairment; monitor (esp. in elderly). Elderly. Labor & delivery. Pregnancy. Nursing mothers.
Avoid within 2 weeks of MAOIs, tricyclic antidepressants. Avoid other short-acting sympathomimetic aerosol bronchodilators, epinephrine. Antagonized by β-blockers. Caution with other drugs that may lower serum potassium (eg, diuretics). Monitor digoxin.
Accidental injury, bronchitis, dizziness, pain, pharyngitis, rhinitis, vomiting; paradoxical bronchospasm, hypersensitivity reactions, cardiovascular effects, hypokalemia.
Vials (YES); HFA (NO)
Inhaler w. actuator (80inh)—8.4g, (200 inh)—15g; Soln 0.31mg/3mL, 0.63mg/3mL, 1.25mg/3mL—24 vials; Concentrate 1.25mg/0.5mL—30 vials
Clinical Pain Advisor Articles
- Chronic Neuropathic Pain Updated Classification by IASP for ICD-11
- Buprenorphine-Naloxone Found to Be More Cost-Effective Than Extended-Release Naltrexone
- Ultrasound-Guided C2 Coblation May Be Effective for Cervicogenic Headache
- Meta-Analysis of Opioid Treatment for Chronic Noncancer Pain
- Opioids Found to Increase Risk for Community-Acquired Pneumonia, Particularly in HIV
- Reviewing the Use of Buprenorphine in Perioperative Pain Management
- Early Physical Therapy for Musculoskeletal Pain May Reduce Opioid Use
- External Trigeminal Nerve Stimulation May Alleviate Migraine Pain
- IASP Updates Diagnosis Criteria for Chronic Primary Pain for ICD-11
- Galcanezumab Provides Persistent Preventive Effects in Episodic, Chronic Migraine
- Comparable Analgesia With Low-Dose IV Ketamine, Morphine for Acute Pain
- Benzodiazepines, if Prescribed, May Not Affect Methadone Treatment Retention
- When Opioid Prescribing Guidelines Become Rules
- IV Fluid Confers No Significant Treatment Effect on Migraine Pain
- American Headache Society Releases Position Statement on Novel Preventive and Acute Migraine Treatments